Introduction
Ovarian cancer is one of the most common malignant cancer among women. It causes higher mortality than any other gynecological malignat tumors. About 70% of the patients are found to have been in advanced-stages (Stage III and IV) by the time of diagnosis. And 70% of the patients have recurrence eventhough they go through primary cytoreductive surgery and chemotherapy. With the alteration of life style, increasing envirenmental pollution, application of assisted reproductive technique and oversue of ovulation drugs, the morbidity of ovarian cancer is increased year by year. Hence, It is urgent to seek diagnosis methods with good sensitivity and high specificity for ovarian cancer, and to enhance the diagnosis of primary and reoccurent ovarian cancer, which in turn helps in timely and accruate detection and treatment of the disease.
At present diagnosis of ovarian cancer commonly relies on the detection of CA125 in blood serum. However, CA125 concentration is increased in only 50%-60% stage I patients [1] . As a single marker, its positive predictive value is even less than 10%, and this value could be only up to 20% in combination with ultrasonic inspection, not to mention the possibility of false positive results. Hence To the best of our knowledge, it is rarely reported around the world about the application feasibility of WCX kit(Bruker Daltonics GraBH) in commbinition with matrixassisted laser desorption/ionization time-of-fligh-t mass spectrometry (MALDI-TOF-MS) technology. For this reason, the present study combined these two technologies to detect the diferentially expressed protein peaks in the serum of control group and patients with primary and reoccurent ovarian cancer so as to build a diagnosis model with higher sensitivity and specificity, and to decrease the mortality from ovarian cancer. 3, 5, 30 and 11, respectively. The age of the patients ranged from 38-83 years old, with an averange of 55.7 years. The positive control group consisted of forty patients who underwent surgery and were pathologically diagnosed as benign cystic ovarian at the same period of time with age range from 30-77 years old and averange age of 52.6 years. The normal control group consisted of forty healthy patients who underwent physical examination with age range from 32-76 years old and averange age of 52.8 year. The age of these tree groups was not significantly different (P>0. 05).
Materials and methods

2
1. Recurrent ovarian cancer group
A total of 21 patients who had recurrence of ovarian cancer 6 months after comprehensive treatment and clinical complete response were screened. The diagnosid standards were 1) The increase of CAI; 2) the occurrence of pleural and ascitic fluid; 3) the detection of tumor by physical examination; 4) the detection of tumor by imaging technique; 5) intestinal obstruction with unknown causes [2] . Tumor would be considered to be recurrent as long as two situations above occurred. The 3, 4, 8, 6 , respectively. Among them, 9 had serous cystadenocarcinoma, 4 had mucinous cystadenocarcinoma, 4 had clear cell carcinoma, 4 had undifferentiated carcinoma. And 12 cases were in midium differentiation level, 9 in low differentiation level.
All patients underwent surgery upon the diagnosis and were validated pathologically after the surgery. They had standard chemotherapy treatment for at least 6 courses. Eighteen patients with complete clinical remission who randomly visited our hospital at the same period were selected as control. The age range was 42-70 years old, with average of 61 years. There was no significant age difference between these two groups (P>0. 05).
Chemicals and instrument
M B -W C X k i t ( N o . 2 2 3 9 8 3 ) , t a r g e t f o r M T PAnchorchip800/384 and MALDI-TOFMS were all from Bruker Dahonics Ltd (Germany). Acetone, methanol, isopropanol, acetonitrile, trifluoroacetic acid, methanoic acid, etc were all of HPLC level and purchased from TEDIA, USA and Schadau, Spanish. Substrate was freshly prepared by dessolving HCCA (Bruker Dahonics, Germany) in ethanolalcohol: acetone (2:1) solvent to a concentration of 0. 3 mg/mL.
3. Blood serum sample collection
The fasting blood was collected from patients with primary ovarian cancer, benign ovarian tumor, recurrent ovarian cancer (before the second line chemotherapy or secondary cytoreductive surgery), the normal control and patients who had an clinical complete remission. The blood was then refrigerated within 30 min at 4 曟 for 2 h, centrifuged at 4 曟 for 20 min at 12 000 rpm. The obtained serum was placed in EP tubes and kept in refrigerator at -80 曟 until use.
4. Blood sample processing procedure
The processing procedures of the blood sample were as the following steps: 1)The suspension of weak cationic magnetic beads were throughly mixed up by fluctuating the tube; 2) Ten 毺 L binding solution of magnetic beadbased WCX+10 毺 L MB-WCX_beads was added into 200 毺L PCR tube, mixed up by pipetting up and down, then 5 毺L of blood serum were added, pipetting up and down for at least 5 times, inculbated the tube for 5 min; 3) The PCR tube was then placed in magnetic bead separator (MBS) for 1 min, the unbound solution were discarded without touching or sucking the magnetic beads; 4)100 毺L of MB-WCX wash solution was added into PCR tube, shuttled on MBS for 10 times. The magnetic beads could be seen attached on the wall of tube, and the unbound solution were discarded. This procedure was reduplicated twice; 5) The PCR tube was then taken down from MBS, 5 毺L elution solution was added to wash the attached magnetic beads by pipetting up and down for 10 times. The tube was then put into MBS again, allowing the magnetic beads adhering onto the wall of tube, and the supernantant was then transferred in an clean centrifuge tube. 6) 5 毺L of stablization solution was then added into the centrifuge tube and mixed up by pipetting up and down; 7) 1 毺L of magnetic beads elution solution along with 10 毺 L substrate was totally mixed up and 0. 5-1 毺L injectable suspension were spotted onto the target, dried at room temperature.
5. MALDI-ToF-MS detection
Autoflex control parameters were set as follows: LP-Clinprot. par as the selection methods, MTPAnchorchip800/384 as the target, the energy of the laser was adjusted to about 60%. The detection mass range (Mr) is 1 k-12 kDa; The resulting images were analyzed by Autoflex analysis and ClinProTools software.
Results
1. Construction of diagnosis model of spectra peak pattern for ovarian cancer
1. 1. primary ovarian cancer
The blood serum protein patterns obtained from patients with primary ovarian cancer, benign ovarian tumor and the heathy control were analysed and compared using ClinProTools software. The group of the neutral/benign tumor patiens and the healthy control were combined into one group as the expressed blood serum protein patterns from this two groups showed no significant variations. In the mass range (Mr) 
1. 2. recurrent ovarian cancer
Comparing the recurrent group with the complete clinical remission group, ten differentially expressed protein peaks were detected in the Mr of 1 000-12 000 Da (Table 2) Blood serum of 8 early stage primary ovarian cancer patients were treated with the same experimental methods and the mass spectra were obtained. Seven cases were predicted as ovarian cancer using the diagnosis model showing a accuracy of 87.50%.
2. 2. Recurrent ovarian cancer
Blood serum of 9 recurrent ovarian cancer patients without pelvic or abdominal mass were treated with the same experimental methods and the mass spectra were obtained. Eight cases were predicted as recurrent ovarian cancer using the diagnosis model showing an accuracy of 88.89%. 
Discussion
Present researches show that the development of tumor is a muti-stage process affected by several factors (including envirenmental factor, genetic factor, etc), leading to the activation of proto-oncogene and the inactivation of cancer suppressor gene. In the invasive development of tumor cells, a large number of protein molecules are involved in the regulation, apoptosis and transfer. At the early stage of tumor without any symtom, the protein level has been changed, which could be used as clinical early diagnosis inde. Hence, analysing and detecting tumor protein could greatly enhance the early detection rate of tumor.
Besides recurrent ovarian cancer, the inducement and development of malignant tumour is an muti-stage process involving a lot of genes. The proto-oncogene is activated and the canser suppressor is inactivated under the effect of muti-factors. In the aggressive development of tumor cells, there is an decrease in cell division regulation machanism and increase in the ability to invade towards the surrounding tissue and to transfer distantly [3, 4] .
In the present research, The results from present study is different from other studies, in which combined technologies like SELDI-TOF-MS, protein chic and SVM was applied to some extent [5, 6] . It may be due to the experimental error, but the specific machanism remains to be discussed. For the existence of such error among studies, some researchers [7] think that it is necessary for large-scaled, forwardlooking, multicentric clinical experiments so as to validate and standardise this technology.
